|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Interestingly, the most common of BRAF mutation (V599E) has not been identified in tumors with K-ras mutations.
|
14513361 |
2003 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF(V599E) mutation did not coexist with alterations in any of the RAS genes in any of the tumors.
|
12881714 |
2003 |
|
rs113488022
|
|
Neoplasms
|
T |
0.800 |
GeneticVariation
|
CLINVAR |
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
|
15035987 |
2004 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Detection of the V600E mutation in a colorectal MSI-H tumour argues against the presence of a germline mutation in either the MLH1 or MSH2 gene.
|
15342696 |
2004 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
We found a high rate of V559E mutations in papillary thyroid carcinomas (47%), one V599E mutation in a well-differentiated gastric endocrine carcinoma (malignant carcinoid), but no activating BRAF mutations in all other endocrine tumors examined.
|
15613458 |
2004 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery.
|
15272920 |
2004 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
However, CIMP-high unstable tumors were significantly more likely than their stable counterparts to be KRAS2 wild type, TP53 wild type, poorly differentiated, proximally located, occur at lower stages, and have the BRAF V600E mutation (64.1% vs 17.6%).
|
16143123 |
2005 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
We detected one 1796 T-->A BRAF mutation that led to a substitution of valine by glutamic acid at position 599 (V599E) in 40 primary neuroendocrine GEP tumors (3%).
|
15842051 |
2005 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
We were able to detect the V599E mutation in genomic DNA from paraffin-embedded melanoma samples and could routinely detect this mutation in fine-needle aspirations of melanoma tumors.
|
15737846 |
2005 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Activating point mutation of the BRAF gene resulting in V600E (previously designated as V599E) is a common event in thyroid papillary carcinoma, being found in approx 40% of this tumor.
|
16299399 |
2005 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Microsatellite-unstable tumors</span> were associated with an excellent 5-year survival whether the V600E mutation was present or absent (76.2% and 75.0%, respectively).
|
16024606 |
2005 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
A subset of tumors from a total of 55 collected (25 polyps and 30 cancers) from 43 individuals across 11 families underwent pathology review, examination for V599E using allele-specific polymerase chain reaction, and for methylation of the MINT31 CpG island.
|
15765445 |
2005 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
The most prevalent BRAF alteration, V599E, occurred only in tumors with MSI.
|
16015629 |
2005 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Thus, these studies identify the me</span>chanistic underpinnings by which mutant (V599E)B-RAF promotes melanoma development and show the effectiveness of targeting this protein to inhibit melanoma tumor growth.
|
15781657 |
2005 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumours containing wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response).
|
16880785 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutated BRAF (BRAF(V600E)) is a potential immunotherapeutic target for melanoma because of its tumor specificity and expression in the majority of these lesions derived from different patients.
|
16540682 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
No statistically significant correlation was found among the presence of B-RAF (V600E) and gender, tumor node metastasis (TNM), multicentricity of the tumor, stage at diagnosis and outcome.
|
16728573 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
While univariate analysis showed the BRAF(V600E) mutation was associated with tumour recurrence (21% with mutation vs 7% without mutation; P = 0.037), this association was not shown following multivariate analyses adjusting for the clinicopathological prognostic factors of age, gender, tumour size, extrathyroid extension, multifocality and lymph node metastasis.
|
16918957 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
We have concluded that BRAF(V600E) is a new prognostic factor in PTC that correlates with a high risk of recurrences and less differentiated tumours due to the loss of NIS-mediated (131)I uptake.
|
16601293 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Of 33 Spitzoid melanomas, only 1 showed the V600E mutation in the B-RAF gene (1 of 33 tumors; 3%).
|
16421887 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
These findings indicate that adenomas might be less important in the cancer development in the group of families with BRAF-V600E mutations and indirectly support a previous hypothesis that tumors might develop through the hyperplastic polyp-serrated adenoma pathway.
|
17119056 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
To answer this question, the BRAF(V600E) mutational status of individual tumor foci was examined.
|
16983703 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis was analyzed.
|
17972530 |
2007 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF V599E mutation in histologic samples was found in 5 (24%) of 21 SBTs, 1 (33%) of 3 MPSCs, 1 (17%) of 6 endometrioid carcinomas, but not detected in 42 conventional serous carcinomas, 12 mucinous borderline tumors, 10 mucinous, and 10 clear-cell carcinomas.
|
17309670 |
2007 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Associations with the BRAF(T1799</span>A) mutation (P<0.05) were as follows: low tumor thickness (odds ratio (OR)=3.3); low mitotic rate (OR=2.0); low Ki67 score (OR=5.0); low PH3 score (OR=3.3); superficial spreading melanoma (OR=10.0); pigmented melanoma (OR=3.7); a lack of history of solar keratoses (OR=2.7); a location on the trunk (OR=3.4) or extremity (OR=2.0); a high level of self-reported childhood sun exposure (OR=2.0); < or =50 years of age (OR=2.5); and fewer freckles (OR=2.5).
|
17159915 |
2007 |